Exact Sciences may have had disappointing Q3 earnings, but its liquidity cushions and new product approval indicate strong ...

Highlights:,Cologuard Plus™ outperforms other noninvasive screening ... sed do eiusmod tempor incididunt ut labore et dolore ...

Exact Sciences stock collapsed Wednesday after the Cologuard maker reported light third-quarter sales and cut its full-year ...

Exact Sciences shares plunged Wednesday after the maker of Cologuard reported widening losses and cut its outlook.

The biomedical giant best known for its Cologuard at-home colon cancer screening test reported a loss of $38.2 million, or $0.21 per share, on revenue of $708.7 million.

Exact Sciences' Q3 report led to a ~25% drop in share price, due to a slight guidance cut and narrow revenue miss. Learn more ...

Puneet Souda’s rating is based on the expectation of broader adoption and higher volumes for Exact Sciences’s Cologuard Plus (CG+), which is anticipated to have higher specificity compared to ...

This approach contributed to strong growth in Cologuard test utilization among rescreen patients and within care gap programs during the third quarter. Exact Sciences received FDA approval for the ...

Exact Sciences Corp ( (EXAS) ) has released its Q3 earnings. Here is a breakdown of the information Exact Sciences Corp presented to its ...

What's going on with Exact Sciences? Exact Sciences is best known for Cologuard, its at-home, non-invasive stool test for colorectal cancer. The company has helped screen millions of eligible ...

On Friday, Exact Sciences Corp (NASDAQ:EXAS) maintained its positive outlook from Leerink Partners following the U.S. Food and Drug Administration's (FDA) approval of the company's Cologuard Plus (CG+ ...

On Monday, Exact Sciences (NASDAQ:EXAS) stock received a reiterated Buy rating and an $82.00 price target from BTIG. The endorsement follows the recent approval by the FDA of Cologuard Plus, Exact ...